AR018002A1 - Composicion farmaceutica que comprende un anticonvulsivo y una resina de intercambio ionico para el tratamiento de la epilepsia, compuestos, uso de lapirrolidona polivinilica y proceso para preparar la composicion - Google Patents

Composicion farmaceutica que comprende un anticonvulsivo y una resina de intercambio ionico para el tratamiento de la epilepsia, compuestos, uso de lapirrolidona polivinilica y proceso para preparar la composicion

Info

Publication number
AR018002A1
AR018002A1 ARP980103399A ARP980103399A AR018002A1 AR 018002 A1 AR018002 A1 AR 018002A1 AR P980103399 A ARP980103399 A AR P980103399A AR P980103399 A ARP980103399 A AR P980103399A AR 018002 A1 AR018002 A1 AR 018002A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
epilepsy
compounds
treatment
ion exchange
Prior art date
Application number
ARP980103399A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR018002A1 publication Critical patent/AR018002A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

Una composicion farmacéutica que comprende un compuesto de formula (I) o una sal del mismo, donde: R1 y R2 son independientemente fenilo o 4-fluorfenilo;R3 es hidrogeno, alquilo C1-C6 o metoxicarbonilo; R4 es hidrogeno o metilo; en asociacion conuna resina de intercambio ionico y opcionalmente, ademásexcipientes o portadores farmacéuticamente aceptables; util para el tratamiento de la epilepsia, compuestos, uso de la pirrolidona polivinilica para mejorar lasensacion bucal de una composicionfar macéutica y proceso para preparar la composicion.
ARP980103399A 1997-07-24 1998-07-13 Composicion farmaceutica que comprende un anticonvulsivo y una resina de intercambio ionico para el tratamiento de la epilepsia, compuestos, uso de lapirrolidona polivinilica y proceso para preparar la composicion AR018002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702793A SE9702793D0 (sv) 1997-07-24 1997-07-24 Novel formulation

Publications (1)

Publication Number Publication Date
AR018002A1 true AR018002A1 (es) 2001-10-31

Family

ID=20407822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103399A AR018002A1 (es) 1997-07-24 1998-07-13 Composicion farmaceutica que comprende un anticonvulsivo y una resina de intercambio ionico para el tratamiento de la epilepsia, compuestos, uso de lapirrolidona polivinilica y proceso para preparar la composicion

Country Status (11)

Country Link
US (1) US6193962B1 (es)
EP (1) EP1009396B1 (es)
JP (1) JP2001510798A (es)
AR (1) AR018002A1 (es)
AT (1) ATE214600T1 (es)
AU (1) AU8371098A (es)
DE (1) DE69804324T2 (es)
MY (1) MY120751A (es)
SE (1) SE9702793D0 (es)
WO (1) WO1999004779A1 (es)
ZA (1) ZA986213B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710280A (zh) * 2019-10-10 2021-11-26 美国倍利年制药有限公司 基于微粉化药物树脂酸盐的药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB857194A (en) * 1957-07-05 1960-12-29 Clinical Products Ltd Therapeutic agents comprising ion-exchange resins
US3100738A (en) * 1961-08-09 1963-08-13 Neisler Lab Inc Uniform release process
US4714620A (en) 1986-12-12 1987-12-22 Warner-Lambert Company Soft, sugarless aerated confectionery composition
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
ZA908490B (en) 1989-10-27 1991-07-31 Fisons Corp Use of arylalkylamides in the treatment of neurodegenerative diseases
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
GB9104042D0 (en) 1991-02-26 1991-04-10 Abbott Lab Taste-masked buflomedil preparation
FR2676364B1 (fr) 1991-05-17 1993-09-10 Lafon Labor Composition pharmaceutique a base de derives d'aminobutanone.
SE9103110D0 (sv) * 1991-10-24 1991-10-24 Kabi Pharmacia Ab New drug formulation
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
US5455049A (en) 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder

Also Published As

Publication number Publication date
DE69804324D1 (de) 2002-04-25
EP1009396A1 (en) 2000-06-21
JP2001510798A (ja) 2001-08-07
AU8371098A (en) 1999-02-16
WO1999004779A1 (en) 1999-02-04
ZA986213B (en) 2000-01-13
EP1009396B1 (en) 2002-03-20
DE69804324T2 (de) 2003-02-27
ATE214600T1 (de) 2002-04-15
US6193962B1 (en) 2001-02-27
SE9702793D0 (sv) 1997-07-24
MY120751A (en) 2005-11-30

Similar Documents

Publication Publication Date Title
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
CO5011115A1 (es) Compuestos y metodos quimioquina
AR011093A1 (es) Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso.
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
NO2013002I1 (no) Aklidinium haogenid (Aklidinium bromid)
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
PE20020771A1 (es) Pirrolidina fusionada con ciclopropilo como inhibidores de dipeptidil peptidas iv
GEP20094675B (en) Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
NO942376L (no) Terapeutiske midler
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
SE0102055D0 (sv) New Compounds
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
PL341539A1 (en) Heterocyclic toxins of topoisomerases
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
DK0707570T3 (da) Isoquinolinderivater som terapeutiske midler
AR018002A1 (es) Composicion farmaceutica que comprende un anticonvulsivo y una resina de intercambio ionico para el tratamiento de la epilepsia, compuestos, uso de lapirrolidona polivinilica y proceso para preparar la composicion
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
AR026451A1 (es) Compuestos heterociclicos sililados
DK0802920T3 (da) Fusacandin-antisvampemidler
TR200000154T2 (tr) 2,4,4-Trisübstitüe-1,3-Dioksolan mantar önleyiciler.
NZ513724A (en) Anticonvulsant derivatives useful in treating essential tremor
CO5261620A1 (es) Compuestos de carbapenem, uso del mismo y compuestos intermedios para el mismo
ATE167873T1 (de) Neue heterocyclische acyldipeptide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
TH23898A (th) วิธีการหยุดยั้งการออกฤทธิ์ของ il-6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal